Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.62 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 2/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | F3 | P13726 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3438123 | 1.00 | CYP1A2 (0.70) | CYP1A2RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL13777344 | 1.00 | CYP1A2 (0.70) | CYP1A2RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL16788877 | 0.96 | CYP1A2 (0.76) | CYP1A2RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL1523794 | 0.96 | CYP1A2 (0.76) | CYP1A2RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL1523796 | 0.96 | CYP1A2 (0.76) | CYP1A2RAB9ANPC1MAPTSMN1; SMN2 | |
| Acetic Acid SCHEMBL6898300 | 0.92 | CYP1A2 (0.60) | CYP1A2RAB9ANPC1MAPTSMN1; SMN2 | |
| Acetic Acid SCHEMBL6898297 | 0.92 | CYP1A2 (0.60) | CYP1A2RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL10742846 | 0.84 | HPGD (0.60) | CYP1A2RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL10743967 | 0.84 | HPGD (0.60) | CYP1A2RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL10742854 | 0.84 | HPGD (0.60) | CYP1A2RAB9ANPC1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194882-A1 | Process For Production of 2-Benzylphenol Compound | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2008-08-14 | — | — | US | claimed |
| EP-1810957-A1 | METHOD FOR PRODUCING 2-BENZYLPHENOL COMPOUND | Ihara Chemical Industry Co., Ltd. (JP) | 2007-07-25 | — | — | EP | claimed |
| US-7807856-B2 | Process for production of 2-Benzylphenol compound | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20080194882-A1 | Process For Production of 2-Benzylphenol Compound | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2008-08-14 | — | — | US | disclosed |
| EP-1810957-A1 | METHOD FOR PRODUCING 2-BENZYLPHENOL COMPOUND | Ihara Chemical Industry Co., Ltd. (JP) | 2007-07-25 | — | — | EP | disclosed |
| WO-2007072089-A1 | MGLUR5 ANTAGONISTIC CARBAMOYL-OXIME DERIVATIVES | RICHTER GEDEON VEGYÉSZETU GYÁR RT. (HU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194882-A1 | Process For Production of 2-Benzylphenol Compound | CYP1B1, CYP4B1, CYP1A1 | CYP1A2 17/4885RAB9A 1012/4885NPC1 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.